Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Prometheus Laboratories Inc.

Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 1995
Status: Acquired

BioCentury | Oct 25, 2022
Management Tracks

Williamson made president and CBO of Triumvira

Plus new heads of strategy, CMC at Actinium, and updates from Telegraph Hill and Sebela
BioCentury | Jan 13, 2020
Politics, Policy & Law

Supreme Court declines to clean up its IP mess

The Supreme Court had a chance but decided not to clarify what kinds of diagnostics can be patented
BioCentury | May 10, 2019
Product Development

Congress pushes to reform patent eligibility, biotechs say not enough

Hopes for revitalizing diagnostics are on hold, as biotechs ask Congress for bigger patent reforms.
BioCentury | Mar 5, 2019
Financial News

Secura Bio closes $145M financing

BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

BioCentury | Jan 25, 2019
Politics, Policy & Law

101 problems with patent eligibility

Why diagnostic innovation needs Congress to fix patent law’s Section 101
BioCentury | Sep 29, 2018
Politics, Policy & Law

Patent law 101

New guidance may make it easier to patent diagnostics, biomarkers and natural products
BioCentury | Jul 15, 2017
Finance

Biome buddies

Why Enterome spun out microbiome Dx assets into JV with Nestlé
BioCentury | Apr 22, 2017
Politics, Policy & Law

Shall we dance?

What’s at stake as SCOTUS considers the biosimilar ‘patent dance’
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

24th BioCentury Back to School Issue: Revolutionize clinical development
Items per page:
1 - 10 of 163